Immediate Impact
1 by Nobel laureates 60 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
2024 Standout
Works of Ferdinand Haslbauer being referenced
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ferdinand Haslbauer | 207 | 77 | 45 | 83 | 26 | 287 | |
| M. Campone | 127 | 85 | 31 | 78 | 21 | 214 | |
| A. Nielsen | 63 | 45 | 22 | 74 | 27 | 306 | |
| Marco Brugia | 208 | 122 | 10 | 113 | 30 | 334 | |
| A. Astone | 233 | 81 | 13 | 52 | 22 | 334 | |
| S. Sisti | 51 | 62 | 72 | 88 | 30 | 324 | |
| Šárka Svobodová | 129 | 60 | 20 | 75 | 27 | 293 | |
| A. Stopeck | 236 | 80 | 10 | 67 | 20 | 287 | |
| V. Leonardi | 181 | 81 | 14 | 33 | 33 | 257 | |
| E. Seyrek | 79 | 51 | 11 | 46 | 22 | 260 | |
| Gordana Petrushevska | 83 | 30 | 6 | 63 | 39 | 237 |
All Works
Login with ORCID to disown or claim papers
Loading papers...